SEC-sourced researchBeta
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Company comparison ↗
Data passport
- CIK
- 0001157601
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 28, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 0.0000 | Feb 19, 2026 |
| December 2024 | 180,133,000.0000 | Feb 19, 2026 |
| December 2025 | 958,403,000.0000 | Feb 19, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 958,403,000.0000 | -288,284,000.0000 | -189,553,000.0000 | 1,259,589,000.0000 | 656,900,000.0000 | Feb 19, 2026 |
| December 2024 | 180,133,000.0000 | -465,892,000.0000 | -455,572,000.0000 | 1,042,247,000.0000 | 287,864,000.0000 | Feb 19, 2026 |
| December 2023 | 0.0000 | -373,630,000.0000 | -324,230,000.0000 | — | — | Feb 19, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $958.4M | December 2025 | Feb 19, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $180.13M | December 2024 | Feb 19, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$288.28M | December 2025 | Feb 19, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$189.55M | December 2025 | Feb 19, 2026 | 10-K |
| Total assetsAssets | $1.26B | December 2025 | Feb 19, 2026 | 10-K |
| Total liabilitiesLiabilities | $656.9M | December 2025 | Feb 19, 2026 | 10-K |